Literature DB >> 20162647

Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.

Raymond Wai-Yin Sun1, Carrie Ka-Lei Li, Dik-Lung Ma, Jessie Jing Yan, Chun-Nam Lok, Chung-Hang Leung, Nianyong Zhu, Chi-Ming Che.   

Abstract

In the design of physiologically stable anticancer gold(III) complexes, we have employed strongly chelating porphyrinato ligands to stabilize a gold(III) ion [Chem. Commun. 2003, 1718; Coord. Chem. Rev. 2009, 253, 1682]. In this work, a family of gold(III) tetraarylporphyrins with porphyrinato ligands containing different peripheral substituents on the meso-aryl rings were prepared, and these complexes were used to study the structure-bioactivity relationship. The cytotoxic IC(50) values of [Au(Por)](+) (Por=porphyrinato ligand), which range from 0.033 to >100 microM, correlate with their lipophilicity and cellular uptake. Some of them induce apoptosis and display preferential cytotoxicity toward cancer cells than to normal noncancerous cells. A new gold(III)-porphyrin with saccharide conjugation [Au(4-glucosyl-TPP)]Cl (2a; H(2)(4-glucosyl-TPP)=meso-tetrakis(4-beta-D-glucosylphenyl)porphyrin) exhibits significant cytostatic activity to cancer cells (IC(50)=1.2-9.0 microM) without causing cell death and is much less toxic to lung fibroblast cells (IC(50)>100 microM). The gold(III)-porphyrin complexes induce S-phase cell-cycle arrest of cancer cells as indicated by flow cytometric analysis, suggesting that the anticancer activity may be, in part, due to termination of DNA replication. The gold(III)-porphyrin complexes can bind to DNA in vitro with binding constants in the range of 4.9 x 10(5) to 4.1 x 10(6) dm(3) mol(-1) as determined by absorption titration. Complexes 2a and [Au(TMPyP)]Cl(5) (4a; [H(2)TMPyP](4+)=meso-tetrakis(N-methylpyridinium-4-yl)porphyrin) interact with DNA in a manner similar to the DNA intercalator ethidium bromide as revealed by gel mobility shift assays and viscosity measurements. Both of them also inhibited the topoisomerase I induced relaxation of supercoiled DNA. Complex 4a, a gold(III) derivative of the known G-quadruplex-interactive porphyrin [H(2)TMPyP](4+), can similarly inhibit the amplification of a DNA substrate containing G-quadruplex structures in a polymerase chain reaction stop assay. In contrast to these reported complexes, complex 2a and the parental gold(III)-porphyrin 1a do not display a significant inhibitory effect (<10%) on telomerase. Based on the results of protein expression analysis and computational docking experiments, the anti-apoptotic bcl-2 protein is a potential target for those gold(III)-porphyrin complexes with apoptosis-inducing properties. Complex 2a also displays prominent anti-angiogenic properties in vitro. Taken together, the enhanced stabilization of the gold(III) ion and the ease of structural modification render porphyrins an attractive ligand system in the development of physiologically stable gold(III) complexes with anticancer and anti-angiogenic activities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162647     DOI: 10.1002/chem.200902741

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  18 in total

1.  DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets.

Authors:  Sze-Tin Von; Hoi-Ling Seng; Hong-Boon Lee; Seik-Weng Ng; Yusuke Kitamura; Makoto Chikira; Chew-Hee Ng
Journal:  J Biol Inorg Chem       Date:  2011-08-11       Impact factor: 3.358

2.  Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine.

Authors:  Zhen-Feng Chen; Yan-Cheng Liu; Yan Peng; Xue Hong; Hong-Hong Wang; Min-Min Zhang; Hong Liang
Journal:  J Biol Inorg Chem       Date:  2011-09-30       Impact factor: 3.358

3.  [Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties.

Authors:  Maria A Cinellu; Laura Maiore; Mario Manassero; Angela Casini; Massimiliano Arca; Heinz-Herbert Fiebig; Gerhard Kelter; Elena Michelucci; Giuseppe Pieraccini; Chiara Gabbiani; Luigi Messori
Journal:  ACS Med Chem Lett       Date:  2010-07-02       Impact factor: 4.345

4.  The gold (III) porphyrin complex, gold-2a, suppresses WNT1 expression in breast cancer cells by enhancing the promoter association of YY1.

Authors:  Kim Hei-Man Chow; Jing Liu; Raymond Wai-Yin Sun; Paul M Vanhoutte; Aimin Xu; Jie Chen; Chi-Ming Che; Yu Wang
Journal:  Am J Transl Res       Date:  2011-10-13       Impact factor: 4.060

5.  Gold ion-angiotensin peptide interaction by mass spectrometry.

Authors:  Jenny Lee; Lasanthi P Jayathilaka; Shalini Gupta; Jin-Sheng Huang; Bao-Shiang Lee
Journal:  J Am Soc Mass Spectrom       Date:  2012-02-17       Impact factor: 3.109

6.  Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin.

Authors:  Aaron D Lammer; Melissa E Cook; Jonathan L Sessler
Journal:  J Porphyr Phthalocyanines       Date:  2015-01       Impact factor: 1.811

7.  Novel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.

Authors:  Artak Tovmasyan; Nelli Babayan; David Poghosyan; Kristine Margaryan; Boris Harutyunyan; Rusanna Grigoryan; Natalia Sarkisyan; Ivan Spasojevic; Suren Mamyan; Lida Sahakyan; Rouben Aroutiounian; Robert Ghazaryan; Gennadi Gasparyan
Journal:  J Inorg Biochem       Date:  2014-06-27       Impact factor: 4.155

8.  DNA interactions and in vitro anticancer evaluations of pyridine-benzimidazole-based Cu complexes.

Authors:  Jiyong Hu; Chunli Liao; Ruina Mao; Junshuai Zhang; Jin'an Zhao; Zhenzhen Gu
Journal:  Medchemcomm       Date:  2017-12-28       Impact factor: 3.597

9.  Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates.

Authors:  Randall T Mertens; Sean Parkin; Samuel G Awuah
Journal:  Chem Sci       Date:  2020-09-18       Impact factor: 9.825

10.  Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I.

Authors:  Kate J Akerman; Alexander M Fagenson; Vidusha Cyril; Michael Taylor; Mark T Muller; Matthew P Akerman; Orde Q Munro
Journal:  J Am Chem Soc       Date:  2014-04-02       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.